Efficacy and tolerability of an aromatase inhibitor (Anastrozole) therapy to limit the advance of bone maturation related to pathological adrenarche in children with Silver Russell or Prader Willi syndrome

Trial Profile

Efficacy and tolerability of an aromatase inhibitor (Anastrozole) therapy to limit the advance of bone maturation related to pathological adrenarche in children with Silver Russell or Prader Willi syndrome

Not stated
Phase of Trial: Phase II

Latest Information Update: 07 Oct 2017

At a glance

  • Drugs Anastrozole (Primary)
  • Indications Prader-Willi syndrome
  • Focus Therapeutic Use
  • Acronyms ANASILPRA
  • Most Recent Events

    • 07 Oct 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top